• BioArctic published an AAIC 2026 update on Leqembi’s subcutaneous autoinjector program, pointing to efficacy and safety comparable to IV dosing in early Alzheimer’s.
• Once-weekly 500 mg SC dosing met bioequivalence to the approved IV initiation regimen, with a 104% exposure ratio (90% CI: 99.1%-109%).
• Data supported a fully subcutaneous initiation-to-maintenance pathway, with at-home administration positioned to broaden access.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607130002PR_NEWS_USPR_____HS02577) on July 13, 2026, and is solely responsible for the information contained therein.